Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar 14:7:91.
doi: 10.3389/fimmu.2016.00091. eCollection 2016.

Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells

Hans Klingemann  1 , Laurent Boissel  1 , Frances Toneguzzo  1
Affiliations
Review

Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells

Hans Klingemann et al. Front Immunol. .

Abstract

Natural killer (NK) cells are potent cytotoxic effector cells for cancer therapy and potentially for severe viral infections. However, there are technical challenges to obtain sufficient numbers of functionally active NK cells from a patient's blood since they represent only 10% of the lymphocytes and are often dysfunctional. The alternative is to obtain cells from a healthy donor, which requires depletion of the allogeneic T cells to prevent graft-versus-host reactions. Cytotoxic cell lines have been established from patients with clonal NK-cell lymphoma. Those cells can be expanded in culture in the presence of IL-2. Except for the NK-92 cell line, though, none of the other six known NK cell lines has consistently and reproducibly shown high antitumor cytotoxicity. Only NK-92 cells can easily be genetically manipulated to recognize specific tumor antigens or to augment monoclonal antibody activity through antibody-dependent cellular cytotoxicity. NK-92 is also the only cell line product that has been infused into patients with advanced cancer with clinical benefit and minimal side effects.

Keywords: ADCC; NK-92 cells; cancer therapy; cellular cytotoxicity; immunotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Biologistic challenges of obtaining blood NK cells for cell therapy.
Figure 2
Figure 2
aNK, haNK, and taNK.
Figure 3
Figure 3
Biologistics of NK-92 as an “off-the-shelf” cellular therapeutic.
See this image and copyright information in PMC

References

    1. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 5:177ra38. 10.1126/scitranslmed.3005930 - DOI - PMC - PubMed
    1. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 3:95ra73. 10.1126/scitranslmed.3002842 - DOI - PMC - PubMed
    1. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood (2012) 119:2709–20. 10.1182/blood-2011-10-384388 - DOI - PMC - PubMed
    1. Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood (2015) 125:784–92. 10.1182/blood-2014-07-592881 - DOI - PMC - PubMed
    1. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One (2012) 7:e30264. 10.1371/journal.pone.0030264 - DOI - PMC - PubMed